Combination Therapy Of Antibodies Activating Human Cd40 And Antibodies Against Human Pd-l1

Document № Publication date Application №
20160045597 February 18, 2016 14/827044

The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40, and a PD-L1 antibody, and optionally a 3 rd component which comprises as an active ingredient a cytokine inhibitor.